European Society for Medical Oncology Congress

The latest news from ESMO, including researcher interviews and physician perspective.


Meeting News

Addition of M6620 to gemcitabine prolongs PFS in platinum-resistant ovarian cancer

September 29, 2019
BARCELONA, Spain — The addition of the ATR kinase inhibitor M6620 to gemcitabine extended PFS without additional toxicity among patients with…
Meeting NewsPerspective

Immunotherapy-chemotherapy combination may reduce recurrence of triple-negative breast cancer

September 29, 2019
BARCELONA, Spain — The addition of pembrolizumab to neoadjuvant chemotherapy significantly increased the pathologic complete response rate…
Meeting NewsPerspective

Ribociclib-fulvestrant combination extends OS among postmenopausal women with advanced breast cancer

September 29, 2019
BARCELONA, Spain — The addition of ribociclib to fulvestrant significantly extended OS among postmenopausal women with hormone…
Meeting NewsPerspective

Abemaciclib plus fulvestrant extends OS in endocrine therapy-refractory advanced breast cancer

September 29, 2019
BARCELONA, Spain — The addition of abemaciclib to fulvestrant significantly prolonged OS among women with hormone receptor-positive…
Meeting News

Veliparib regimen extends PFS in newly diagnosed high-grade serous ovarian carcinoma

September 29, 2019
BARCELONA, Spain — The addition of veliparib to frontline chemotherapy followed by maintenance with veliparib monotherapy significantly…
Meeting NewsPerspective

Front-line osimertinib improves OS in EGFR-mutated lung cancer

September 28, 2019
BARCELONA, Spain — Osimertinib significantly extended OS compared with standard epidermal growth factor receptor tyrosine kinase inhibitors as…
Meeting NewsPerspective

Immunotherapy combination improves OS compared with chemotherapy in lung cancer subset

September 28, 2019
BARCELONA, Spain — A combination of nivolumab and low-dose ipilimumab significantly improved OS compared with chemotherapy as first-line…
Meeting NewsPerspective

Addition of olaparib to maintenance bevacizumab significantly improves PFS in ovarian cancer

September 28, 2019
BARCELONA, Spain — The addition of olaparib to bevacizumab maintenance therapy after first-line platinum-based chemotherapy and bevacizumab…
Meeting News

Niraparib significantly extends PFS in newly diagnosed advanced ovarian cancer

September 28, 2019
BARCELONA, Spain — Niraparib significantly extended PFS among women with newly diagnosed advanced ovarian cancer, according to results of the…
Meeting NewsPerspective

Surgical exploration ‘highly recommended’ after induction chemotherapy for locally advanced pancreatic cancer

September 28, 2019
BARCELONA, Spain — Four months of induction combination chemotherapy followed by surgical exploration made secondary resection feasible for…